Resonance Health Ltd (AU:RHT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Resonance Health Ltd has successfully acquired TrialsWest, marking a significant advancement in its growth strategy to broaden its presence within the global clinical trials market. The $4 million deal, financed through cash reserves and a new debt facility with NAB, could see additional payments contingent on performance targets. This strategic move is anticipated to drive revenue growth and facilitate both organic and acquisitive expansion, with the TrialsWest team, including its founders, continuing to play a pivotal role.
For further insights into AU:RHT stock, check out TipRanks’ Stock Analysis page.